 Print View Attached Docs: |
|||||||||
| 87285:PNEUMOCOCCAL ANTIBODY, IgG, 14 SEROTYPES | |||||||||
| Alias Names: | Streptococcus pneumoniae Immune Response / Streptococcus pneumoniae Vaccine Response | ||||||||
| Methodology: | Multi-Analyte Fluorescent Detection | ||||||||
| Edit Date: | 6/11/2010 | ||||||||
| Components: | Includes serotypes 1, 3, 4*, 5, 6B*, 7F, 8, 9N, 9V*, 12F, 14*, 18C*, 19F*, 23F* All sesrotypes tested are present in the 23-valent pure polysaccharide pneumococcal vaccine. The serotypes marked with an asterisk are contained in the heptavalent conjugated pneumococcal vaccine. |
||||||||
| Performed: | Monday, Thursday, Saturday | ||||||||
| Released: | 1-4 days after setup at PeaceHealth Laboratories’ reference lab | ||||||||
| CPT Code: | 86317-90 x14 | ||||||||
| Specimen Collection Details | |||||||||
| Collection: | One 7.5 mL serum separator tube (SST). | ||||||||
| Handling: | Allow to clot, centrifuge and separate serum from cells immediately. Label specimen ‘Pre-Vaccine’ or ‘Post-Vaccine.’ | ||||||||
| Stability: | After separation from clot, specimen stable 48 hours ambient, 14 days refrigerated, or 1 year frozen. Avoid repeated freeze/thaw cycles. | ||||||||
| Standard Volume: | 1.5 mL serum. | ||||||||
| Minimum Volume: | 250 µL serum. | ||||||||
| Transport: | Refrigerated. | ||||||||
| Comments: | Pre- and post-pneumococcal vaccine specimens can be submitted separately or together for testing. Post- specimen should be drawn 30 days after immunization and, if shipped separately, must be received within 60 days of the pre-specimen. Label specimens clearly with ‘Pre-Vaccine’ or ‘Post-Vaccine.’ | ||||||||
| Rejection Criteria: | Plasma; other body fluids; severely lipemic, contaminated or hemolyzed specimen. | ||||||||
| Reference Interval: | |||||||||||||||||||
| This assay is designed to use both ‘pre’ and ‘post’ specimens to assess immune responsiveness to vaccination. This test is not designed to determine protection to Streptococcus pneumoniae based on a single specimen. | |||||||||||||||||||
| Long-term protection is generally thought to be associated with a one month post-vaccine response of at least 1 µg/mL in children and adults. Responder status is determined once reaching the minimum level of 1 µg/mL, according to the ratio of post-vaccination to pre-vaccination concentration of pneumococcal IgG antibody, as follows. | |||||||||||||||||||
| A ratio of less than twofold is considered a non-responder. | |||||||||||||||||||
| A ratio of two-to fourfold is a weak responder. | |||||||||||||||||||
| A ratio of fourfold or greater is a good responder. | |||||||||||||||||||